
Edesa Biotech EDSA
$ 5.82
-0.68%
Quarterly report 2025-Q4
added 02-13-2026
Edesa Biotech Cost of Revenue 2011-2026 | EDSA
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Edesa Biotech
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 17.6 K | - | - | 250 K | 819 K | 581 K | 469 K | 57.4 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 819 K | 17.6 K | 366 K |
Quarterly Cost of Revenue Edesa Biotech
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.3 K | 1.47 K | 10 K | 3.78 K | - | - | 3.78 K | - | - | 45.6 K | 65.6 K | 2.8 K | 228 K | 77.6 K | 71.4 K | 78.6 K | 701 K | 120 K | 269 K | 312 K | 571 K | 232 K | 312 K | 95.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 701 K | 1.47 K | 161 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M | ||
|
Verastem
VSTM
|
165 K | $ 5.04 | -4.73 % | $ 349 M | ||
|
Aeterna Zentaris
AEZS
|
90 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
40 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
27.2 M | - | - | $ 866 M | ||
|
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | ||
|
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M | ||
|
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
33.5 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
133 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
100 K | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
71.4 M | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Xenetic Biosciences
XBIO
|
44.8 K | $ 2.72 | -2.86 % | $ 4.63 M | ||
|
XBiotech
XBIT
|
651 K | $ 2.27 | -1.73 % | $ 69.2 M | ||
|
Xeris Pharmaceuticals
XERS
|
42.6 M | $ 5.4 | -3.05 % | $ 866 M | ||
|
X4 Pharmaceuticals
XFOR
|
5.76 M | $ 4.04 | -6.26 % | $ 171 M | ||
|
XOMA Corporation
XOMA
|
143 K | $ 30.17 | -1.18 % | $ 364 M | ||
|
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B | ||
|
22nd Century Group
XXII
|
10.2 M | $ 2.41 | -18.03 % | $ 444 K | ||
|
BioDelivery Sciences International
BDSI
|
23.4 M | - | -4.8 % | $ 255 M | ||
|
Zai Lab Limited
ZLAB
|
191 M | $ 18.0 | 2.8 % | $ 19.7 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
737 K | $ 1.05 | -3.67 % | $ 21.5 M |